INT206440

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2007
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 3.76
Pain Relevance 0.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (MOCS1) small molecule metabolic process (MOCS1) nucleus (MOCS1)
Anatomy Link Frequency
liver 1
MOCS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 33 98.24 Very High Very High Very High
Bioavailability 4 98.20 Very High Very High Very High
diclofenac 3 93.56 High High
Dopamine 40 88.36 High High
antagonist 5 54.00 Quite High
palliative 2 48.96 Quite Low
cytokine 8 39.48 Quite Low
Paracetamol 5 28.68 Quite Low
metalloproteinase 8 28.56 Quite Low
imagery 8 21.00 Low Low
Disease Link Frequency Relevance Heat
Suicidal Behaviour 3 100.00 Very High Very High Very High
Urological Neuroanatomy 24 99.90 Very High Very High Very High
INFLAMMATION 38 98.24 Very High Very High Very High
Obesity 20 95.68 Very High Very High Very High
Diabetes Mellitus 80 95.12 Very High Very High Very High
Insulin Resistance 18 94.52 High High
Syndrome 78 92.32 High High
Adverse Drug Reaction 192 92.08 High High
Gauchers Disease 154 90.08 High High
Coronary Heart Disease 4 87.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is interesting to note that not all known substrates, nor all of those with reactivity in our activity screens, were found to bind to the enzyme in the presence of PAP.
enzyme Binding (bind) of
1) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1847840 Disease Relevance 0 Pain Relevance 0.04
We have studied the human SULT family of enzymes to profile which small molecules are recognized by each enzyme.
enzyme Binding (recognized) of
2) Confidence 0.01 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC1847840 Disease Relevance 0 Pain Relevance 0
Evidence is provided for structural “priming” of the enzyme active site by cofactor binding, which influences the spectrum of small molecules that can bind to each enzyme.
enzyme Binding (bind) of
3) Confidence 0.01 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC1847840 Disease Relevance 0 Pain Relevance 0
By studying the entire family, we discovered new ways in which chemicals interact with each enzyme.
enzyme Binding (interact) of
4) Confidence 0.01 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC1847840 Disease Relevance 0 Pain Relevance 0
We also visualized and compared the detailed structural features that determine which enzyme interacts with which molecule.
enzyme Binding (interacts) of
5) Confidence 0.01 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC1847840 Disease Relevance 0 Pain Relevance 0
After a 15-minute incubation (to allow for interaction between compound and enzyme), a 1-µL substrate addition step initiated the reaction.
enzyme Binding (interaction) of
6) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2970562 Disease Relevance 0 Pain Relevance 0
Compound 13 additionally also reduced the apparent Km by half at a concentration of 10 nM, suggesting that the affinity of the enzyme for the substrate was increased by the inhibitor, consistent with a mode of uncompetitive or mixed-type inhibition.
enzyme Binding (affinity) of
7) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2970562 Disease Relevance 0 Pain Relevance 0
In vivo, enzyme activity is highly regulated at a number of different levels (for example, gene expression and translation, proenzyme activation, enzyme-matrix interactions, endogenous inhibitors, and so on [17]).
enzyme Binding (interactions) of
8) Confidence 0.01 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206387 Disease Relevance 0 Pain Relevance 0.03
ERT quickly advanced in GD, where macrophages were regarded as the primary source for the stored abnormal lipid.23 The first enzyme preparation purified from placental tissue did not yield any significant clinical response, although the total amount of stored lipid was shown to be reduced in liver samples.24 The placental enzyme that contained complex N-linked glycans was largely taken up by the asialoglycoprotein receptors present on hepatocytes.25 Further modification of N-linked oligosaccharide terminals to remove sialic acid residues, that exposed terminal mannose residues, was essential for the internalization of the enzyme by the Gaucher macrophages.26 This modified high-mannose form of enzyme was readily recognized by mannose receptors abundant on the macrophages.27 The first placental derived enzyme product alglucerase (Cere-dase®; Genzyme Inc, Cambridge, MA, USA) was developed based on this principle, and was tested successfully on 12 patients with type 1 GD with improvements in hematological parameters, and the reduction in organ volumes.28 This was followed by two trials on 25 patients with imiglucerase (Cer-ezyme®; Genzyme Inc), a recombinant form of human GC, which differs from native GC with a substitution of histidine instead of arginine at position 495.
enzyme Binding (recognized) of in liver associated with gauchers disease
9) Confidence 0.01 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909498 Disease Relevance 0.29 Pain Relevance 0
Chaperone molecules are thus often weak inhibitors which bind at neutral pH during biosynthesis of the enzyme and stabilize it for delivery to the lysosome; in the lysosome, the dramatic increase in hydrogen ion concentration is proposed to favor dissociation of the inhibitor, thus allowing restitution of enzyme function.73
enzyme Binding (bind) of
10) Confidence 0.00 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010821 Disease Relevance 0.20 Pain Relevance 0
However, we found the strongest effect modification for MPO, an enzyme that binds to the vessel wall and depletes vascular NO bioavailability (Rudolph et al. 2006).
enzyme Neg (NO) Binding (binds) of associated with urological neuroanatomy and bioavailability
11) Confidence 0.00 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2599761 Disease Relevance 0.99 Pain Relevance 0.09
MPO is an enzyme that binds to the vessel wall, critically modulates structural and humoral integrity of the vessel wall, and depletes vascular NO bioavailability (Eiserich et al. 2002; Nicholls and Hazen 2005; Rudolph et al. 2006).
enzyme Neg (NO) Binding (binds) of associated with urological neuroanatomy and bioavailability
12) Confidence 0.00 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2599761 Disease Relevance 0.64 Pain Relevance 0.05
It is undisputed that direct interaction between a chemical and a protein, for example, noncovalent binding of a drug to the active center of an enzyme, is a fundamental step in drug effect.
enzyme Binding (binding) of
13) Confidence 0.00 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2704868 Disease Relevance 0.64 Pain Relevance 0.05
Case drugs tend to bind to its peptidase active center and might interfere the suicide regulation [31] of the enzyme itself when the enzyme is over-expressed.
enzyme Spec (might) Binding (bind) of associated with suicidal behaviour
14) Confidence 0.00 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2704868 Disease Relevance 0.50 Pain Relevance 0.05
Case drugs tend to bind to its peptidase active center and might interfere the suicide regulation [31] of the enzyme itself when the enzyme is over-expressed.
enzyme Spec (might) Binding (bind) of associated with suicidal behaviour
15) Confidence 0.00 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2704868 Disease Relevance 0.49 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox